Skip to main content
. Author manuscript; available in PMC: 2018 Dec 28.
Published in final edited form as: Pediatr Res. 2018 May 16;84(3):362–370. doi: 10.1038/pr.2018.26

Table 3.

Alcohol and Substance Use Patterns by Study Group (N=93)

PAE (n=39) No-PAE (n=54) p
Alcohol Use:
12 months prior to enrollment:
AUDIT past 12 months: (Mean ± SD) 10.31 ± 7.74 0.57 ± 0.74 <0.001
AUDIT ≥ 8: n (%) 21 (53.9) 0 (0.0) <0.001
Periconceptional period (1 month around LMP):
AA/day (Mean ± SD) 1.27 ± 2.16 0.0026 ± 0.009 <0.001
AA/drinking day (Mean ± SD) 3.17 ± 2.09 0.86 ± 0.42a <0.001
Number of binge episodes (Mean ± SD) 7.24 ± 8.97 0 ± 0 <0.001
Alcohol use at V1:
AA/day (Mean ± SD) 0.05 ± 0.25 0 ± 0 0.237
AA/drinking day (Mean ± SD) 2.11 ± 2.49 N/A N/A
Number of binge episodes (Mean ± SD) 0.21 ± 1.13 0 ± 0 0.263
Maternal alcohol biomarkers at V1:
GGT (>40 U/L): n (%) 9 (23.1) 0 (0.0) <0.001
PEth (≥ 8 ng/ml): n (%) 4 (10.3) 0 (0.0) 0.028
%dCDT > 2: n (%) 2 (5.1) 0 (0.0) 0.173
Alcohol use at V2:
AA/day (Mean ± SD) 0.004 ± 0.014 0 ± 0 0.077
AA/drinking day (Mean ± SD) 0.97 ± 0.90 N/A N/A
Number of binge episodes (Mean ± SD) 0.03 ± 0.16 0 ± 0 0.324
Maternal alcohol biomarkers at V2:
GGT (>40 U/L): n (%) 4 (10.3) 0 (0.0) 0.028
PEth (≥ 8 ng/ml): n (%) 3 (7.7) 0 (0.0) 0.070
UEtG (≥ 38 ng/ml): n (%) 3 (7.7) 0 (0.0) 0.070
UEtS (≥ 7.2 ng/ml): n (%) 9 (23.1) 0 (0.0) <0.001
%dCDT > 2: n (%) 3 (7.7) 0 (0.0) 0.070
PEth-DBS (≥ 25 ng/ml) 7 (18.0) 0 (0.0) 0.002
Cumulative Alcohol use across pregnancy & periconceptional period:
AA/day (Mean ± SD) 0.44 ± 0.72 0.001±0.004 <0.001
AA/drinking day (Mean ± SD) 3.10 ± 2.12 0.86 ± 0.42a <0.001
Positive for ≥1 biomarker (V1 or V2) n (%) 21 (53.9) 0 (0.0)) <0.001
Substance Use*:
MAT (methadone, buprenorphine): 22 (56.4) 19 (35.2) 0.057
Other opioids (heroin or Rx opioids**): 14 (35.9) 11 (20.4) 0.105
Marijuana: 14 (35.9) 6 (11.1) 0.005
Any tobacco use: 21 (53.9) 15 (27.8) 0.017

MAT, medication assisted therapy; AA, absolute ounces of alcohol (1 standard drink equals approximately 0.5 AA) GGT, gamma-glutamyltranspeptidase; PEth, phosphatidylethanol; UEtG, urine ethyl glucuronide; UEtS, urine ethyl sulfate; %dCDT, disialo carbohydrate deficient transferrin; DBS, dried blood spot

a

sample size is limited to 5 controls who reported light drinking around LMP

*

Either self-reported anytime in pregnancy or a positive urine drug panel at V1 or V2

**

used either as prescribed or recreational use